PDCD1 and Hepatitis: Twenty patients developed irAEs, 16 patients discontinued the use of PD‐1 inhibitors, and 13 patients required corticosteroid therapy, with mainly presented with pneumonitis (11.4%), myocarditis (2.6%), dermatitis (1.7%), neurologic toxicity (2.6%), hepatitis (0.9%), thyroid dysfunction (0.9%), cystitis (0.9%), and renal insufficiency (0.9%).